JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

Начало・Списък с акции・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

29.38 7.23

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

27.4

Максимум

32.56

Ключови измерители
By Trading Economics
Приходи	-85K 53M
Продажби	4.2M 153M
P/E Средно за сектора	15.518 60.328
EPS	0.68
Марж на печалбата	34.53
Служители	182
EBITDA	612K 81M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+26.05% upside

Дивиденти
By Dow Jones
Следващи печалби	6.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	241M 3.2B
Предишно отваряне	22.15
Предишно затваряне	29.38

Настроения в новините

By Acuity

25%

75%

70 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

N/A / 24.28 Подкрепа & съпротива

Catalyst Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.04.2026 г., 23:15 ч. UTC

Значими събития в новините

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

27.04.2026 г., 23:08 ч. UTC

Печалби

Значими двигатели на пазара

LendingClub Shares Gain on 1Q Profit, Revenue Beat

27.04.2026 г., 23:58 ч. UTC

Печалби

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

27.04.2026 г., 23:58 ч. UTC

Печалби

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

27.04.2026 г., 23:56 ч. UTC

Печалби

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

27.04.2026 г., 23:56 ч. UTC

Печалби

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

27.04.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

27.04.2026 г., 23:42 ч. UTC

Пазарно говорене

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

27.04.2026 г., 23:34 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

27.04.2026 г., 23:30 ч. UTC

Пазарно говорене

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

27.04.2026 г., 23:08 ч. UTC

Пазарно говорене

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

27.04.2026 г., 23:02 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

27.04.2026 г., 23:02 ч. UTC

Пазарно говорене

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

27.04.2026 г., 22:42 ч. UTC

Пазарно говорене

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

27.04.2026 г., 22:10 ч. UTC

Печалби

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

27.04.2026 г., 22:09 ч. UTC

Печалби

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

27.04.2026 г., 22:09 ч. UTC

Печалби

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

27.04.2026 г., 22:09 ч. UTC

Печалби

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

27.04.2026 г., 21:56 ч. UTC

Печалби

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

27.04.2026 г., 21:55 ч. UTC

Печалби

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

27.04.2026 г., 21:55 ч. UTC

Печалби

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

27.04.2026 г., 21:44 ч. UTC

Печалби

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

27.04.2026 г., 21:43 ч. UTC

Печалби

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

27.04.2026 г., 21:41 ч. UTC

Печалби

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

27.04.2026 г., 21:41 ч. UTC

Печалби

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

27.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

27.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

27.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

27.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

27.04.2026 г., 20:39 ч. UTC

Печалби

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Сравнение с други в отрасъла

Ценова промяна

Catalyst Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

26.05% нагоре

12-месечна прогноза

Среден 34.5 USD 26.05%

Висок 35 USD

Нисък 33 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Catalyst Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Catalyst Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 24.28Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Настроение

By Acuity

70 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.